Inclusion Criteria:

- signed informed consent form;

- histologically or cytologically confirmed gastric cancer;

- Age 18-75 years;

- Advanced or recurrent, metastatic disease;

- Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;

- Life expectancy of at least 12 weeks;

- At least have one measurable disease(according to RECIST, Response Evaluation
Criteria in Solid Tumors );

- no prior history of chemotherapy or beyond 6 months after the end of systemic
adjuvant treatment;

- Haematopoietic status:

- Absolute neutrophil count > 1.5 x 109/L;

- Platelet count > 90 x 109/L;

- Hemoglobin at least 90g/l;

- Hepatic status:

- Bilirubin ≤ 1.5 x upper limit of normal (ULN);

- AST and ALT ≤ 2.5 times ULN(no liver metastasis), ≤ 5 times ULN (with liver
metastasis);

- ALP ≤ 2.5 times ULN(no liver metastasis), ≤5 times ULN(with liver or bone
metastasis);

- serum albumin ≥ 30g/L;

- Renal status:

- Creatinine ≤ 1.5 times ULN or calculated creatinine clearance, using the
Cockcroft-Gault formula, ≥ 40 mL/min;

- Able to swallow and retain oral medication;

Exclusion Criteria:

- peripheral neuropathy of grade 2 or greater;

- symptomatic brain metastasis;

- known history of uncontrolled or symptomatic angina;

- clinically significant arrhythmias, congestive heart failure, uncontrolled
hypertension (≥ 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic
therapy with oxygen;

- dementia, altered mental status, or any psychiatric condition that would prevent the
understanding or rendering of ICF;

- active or uncontrolled infection;

- pregnant or lactating women;

- dysmetabolism with nanoparticle Albumin-bound paclitaxel or Capecitabine

- unable to swallow and retain oral medication,intestinal Obstruction,alimentary tract
hemorrhage